CS
KNTE

Credit Suisse’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Credit Suisse’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$6 – 3836
2022
Q4 		$6 Sell
1
-164
-99% -$1.34K ﹤0.01% 3811
2022
Q3 		$2K Buy
165
+137
+489% +$1.79K ﹤0.01% 3778
2022
Q2 		$0 Buy
+28
New +$261 ﹤0.01% 4448

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse's KNTE Position: Q1 2023 in Review

Credit Suisse sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2023, closing a stake of 1 share — an estimated $6 sold.

Credit Suisse first reported a position in KNTE in Q2 2022 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 71 funds tracked by Wall St. Rank hold KNTE as of Q1 2023.

  • Credit Suisse reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Kinnate Biopharma Inc. Common Stock share in Q1 2023, an estimated $6.
  • Credit Suisse first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Kinnate Biopharma Inc. Common Stock position peaked at $2K in Q3 2022.
  • 71 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.